Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day.

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

ARK Invest isn’t letting go of its crypto conviction. Fresh filings reveal that the fund scooped another $8.2M worth of ...

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...